Furthermore, higher KLF4 expression is associated with poorer overall survival (OS) in lung cancer patients, as well as reduced progression‐free survival (PFS) in patients undergoing anti‐PD1 (Immune‐checkpoint inhibitor) ICB therapy (Figure 2E), underscoring its prognostic significance. This evidence concerns the gene KLF4 and lung cancer.